Key Insights

Highlights

Treatment Research

2 treatments under study, led by Bemarituzumab

Clinical Risk Assessment

Based on trial outcomes

Moderate Risk

Score: 50/100

Termination Rate

0.0%

0 terminated out of 1 trials

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 0 completed with results

Key Signals

Data Visualizations

Phase Distribution

1Total
Phase 2 (1)

Trial Status

Withdrawn1

Clinical Trials (1)

Showing 1 of 1 trials
NCT06967987Phase 2WithdrawnPrimary

Study Evaluating the Combination of Bemarituzumab + FLOT Chemotherapy in Perioperative Setting for Resectable Stage cT2-T4a or N+ Gastric and GEJ Adenocarcinoma Overexpressing FGFR2b

Showing all 1 trials

Research Network

Common Treatments

  • Bemarituzumab1
  • Bemarituzumab Flot Regimen1

Active Sponsors

  • Amgen Ltd., United Kingdom1
  • Institut Cancerologie de l'Ouest1
  • Institut De Cancerologie De L Ouest1

Top Investigators

Related Conditions

  • Gastric And Gastrooesophageal Junction Adenocarcinomas1
  • Overexpression Fgfr2b1

Activity Timeline